Central Nervous System Biomarkers Market Size, Share & Trends Analysis Report By Type of CNS Biomarkers (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Other Types of CNS Biomarkers), By Applications (Drug Discovery and Development, Personalized Medicine, Other Applications), By End User (Diagnostic Labs, Clinics/Hospitals, Research Centers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Central Nervous System Biomarkers Market Size

The global central nervous system biomarkers market size was valued at USD 6.01 billion in 2025 and is projected to grow from USD 6.47 billion in 2026 to USD 11.66 billion by 2034, registering a CAGR of 7.64% during the forecast period from 2026 to 2034. North America dominated the central nervous system biomarkers market with a market share of 39.2% in 2025.

The key aspects bolstering the expansion of the CNS biomarkers market are the rise in the development of proteomics, genomics, and imaging systems, rising investments from governments and private players, and increasing R&D activities. Some other factors that could potentially proliferate the market growth are the surging prevalence of chronic disorders, the increasing number of initiatives, and the growing geriatric population.

Biomarkers are quantifiable indicators that are used to evaluate and determine pathogenic processes and therapeutic interventions, as well as to predict treatment response. Biomarkers are utilized in numerous scientific disciplines. Biomarkers are used in drug development and regulatory decision-making processes because they can enhance the efficacy of drug discovery and development. Biomarkers also provide information about a patient during virtually all phases of care.

Clinically, central nervous system (CNS) biomarkers are used to screen, monitor, or diagnose the activity of CNS-related diseases to guide molecularly targeted therapy or evaluate therapeutic responses. Biomarkers aid in comprehending the etiology of chronic diseases and their relationship to environmental compounds, as well as identifying subjects at high risk for developing diseases.

Types of CNS Biomarker Insights

The global market is bifurcated into safety biomarkers, efficacy biomarkers, validation biomarkers, and other types of CNS biomarkers. The safety biomarker segment dominates the global market and is projected to exhibit a CAGR of 8.44% over the forecast period. A safety biomarker is a biomarker that is assessed before or during exposure to a pharmaceutical or environmental substance to determine the possibility, presence, or severity of toxicity as a negative side effect. The safety biomarkers have become widely accepted and qualified by regulatory agencies, are increasingly implemented in early clinical trials, play a prominent role in decision-making, and promote the progression of promising therapeutics from preclinical through clinical development.

The other types of CNS biomarkers include predictive and prognostic biomarkers, among others. Predictive biomarkers can identify patients most likely to benefit from a given treatment, sparing other patients from the negative effects of failed medications. A prognostic biomarker indicates an increased probability of a specific population's future clinical event, disease recurrence, or disease progression. Biomarkers for prognosis are measured at a defined baseline, which may include a treatment as a background.

Request Customizationto receive a tailored report.

Application Insights

The global market is divided into drug discovery and development, personalized medicine, and other applications. The drug discovery and development segment is the highest contributor to the market and is estimated to exhibit a CAGR of 8.55% throughout the forecast period. It has been difficult to discover effective treatments for mental disorders. The efficacy of therapeutic interventions can be evaluated using biomarkers that modulate the expression of potential drug targets. Biomarkers can assist in diagnosis, demonstrate target engagement, support disease modification, and monitor for safety. Compared to other areas of drug discovery, the clinical failure rate for new drugs targeting central nervous system (CNS) diseases is even higher. Therefore, these biomarkers that help in drug development are increasing in use, boosting the segment growth.

Precision medicine, commonly called personalized medicine, is among the most promising approaches to tackling diseases. The key aspect contributing to the segment's growth is the rising number of brain and other nervous system cancers. It is one of the emerging fields for CNS biomarkers due to its rising application as a diagnostic tool, which helps recognize the precise biological markers.

End-Users Insights

The global market is segmented into diagnostic labs, clinics/hospitals, and research centers. The diagnostic labs segment owns the highest market share and is estimated to exhibit a CAGR of 8.55% during the forecast period. The increasing prevalence of neurological diseases, government initiatives, and major market players' strategies are the major factors fueling the increase in diagnostic laboratories, thereby increasing the tests performed in these diagnostic laboratories. With the automation and growing emergence of robotics in diagnostic laboratories, a transformation has resulted in increased productivity and lowered the cost of the tests. The market for CNS biomarkers usage in laboratories is also expected to increase due to the collaboration between manufacturers and laboratories to produce innovative products.

Hospitals play a vital role in neurological diagnosis tests, as most patients visit hospitals due to these disorders. The startup cost is not prohibitive for most hospitals, given diagnostics' important clinical and financial benefits. Hence, most of the large-scale and middle-scale hospitals have inbuilt laboratories to conduct the diagnosis of CNS diseases. The major advantage of the diagnosis within the hospitals is that the results are easily accessible to the healthcare professionals to make the required decision.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global market shareholder and is anticipated to exhibit a CAGR of 8.82% during the forecast period. The growing burden of central nervous system (CNS) diseases, the rise in the development of proteomics, genomics, and imaging systems, and the increasing adoption of personalized medicines and therapy are expected to drive the CNS biomarkers market in the region. Likewise, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period. For instance, in May 2021, the Alzheimer's Drug Discovery Foundation (ADDF) announced 11 new investments from October 2020 to March 2021, totaling more than USD 11 million, supporting innovative Alzheimer's drug discovery and biomarker research.

Product launches are another factor for the growth of the market. For instance, in December 2021, the University of British Columbia launched a new test for Alzheimer's disease in Canada. The test measures proteins known as biomarkers in the cerebrospinal fluid enveloping the brain and spinal cord, which could assist with the disease's earlier and more accurate diagnosis. Hence, the market is expected to boost over the forecast period due to the above conditions.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Central Nervous System Biomarkers Market Trends

Europe is estimated to exhibit a CAGR of 8.25% over the forecast period. Factors such as the rising cases of central nervous system (CNS) diseases, the aging population, the increasing demand for efficient products, and favorable initiatives by the key market players are the driving factors for the market growth. As per the report by the German Alzheimer Society, approximately 1.6 million Germans suffer from dementia, with approximately 300,000 new cases each year. Similarly, according to the report, the number of people affected is anticipated to rise to between 2.4 and 2.8 million by 2050 due to shifting demographics and an aging population. Dementia is expected to rise in the coming years, positively impacting the market.

In Asia-Pacific, the growing burden of CNS diseases like Alzheimer's disease, multiple sclerosis, Parkinson's disease, and others is predicted to contribute to the market growth. For instance, according to data from the Dementia in India Report 2020, about 7.6 million people in India will likely be diagnosed with Alzheimer's by 2030. Similarly, the strategic initiatives taken by the key market players, such as partnerships and collaborations in the studied market, are also expected to drive market growth. For instance, in January 2022, Clario and XingImaging, a biomarker imaging company, expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics for Alzheimer's disease (AD) and other neurodegenerative diseases in China. As PET imaging involves imaging markers, such developments contribute to the market's growth.

In South America, the increasing prevalence of diseases is among the prominent aspects contributing to the market growth. For instance, as per the Pan American Health Organization (PAHO), in 2019, the burden of neurological conditions per 100,000 population in Brazil was 20.50. The same source also reports that the burden of Parkinson's disease in 2019 was 1.91 per 100,000 population. Thus, Brazil's neurological disorders burden fuels the region's demand for central nervous system biomarkers.

• Moreover, according to World Population Ageing 2019, the number of people aged above 65 years in 2019 in the Argentina region is 5,035,000 and is expected to reach 9,480,000 by 2050. This increase in the geriatric population is expected to increase the number of individuals affected with neurological disorders in the country, as elderly people are more prone to diseases, thus boosting the market.

List of Key and Emerging Players in Central Nervous System Biomarkers Market